Bis(phosphoramidate diester)-Based Ionizable Lipids for Highly Efficient Lung-Selective mRNA Delivery via Intercellular Transport
Summary
Highly efficient lung-selective mRNA delivery is pivotal for advancing mRNA-based targeted therapy. Here, we report bis(phosphoramidate diester)-based ionizable cationic lipids (bpLs) for lung-specific mRNA delivery via a distinct intercellular transport mechanism. A bpL library is synthesized by modular headgroups (Ha), linkers (Lb), and tails (Tc). In vivo screening identifies the formulated bpLH15L2T8/DOPENP as the top lung-selective lipid nanoparticle (LNP) with superior pulmonary mRNA transfection.
Keywords
Highly efficient lung-selective mRNA delivery is pivotal for advancing mRNA-based targeted therapy. Here, we report bis(phosphoramidate diester)-based ionizable cationic lipids (bpLs) for lung-specific mRNA delivery via a distinct intercellular transport mechanism. A bpL library is synthesized by modular headgroups (Ha), linkers (Lb), and tails (Tc). In vivo screening identifies the formulated bpLH15L2T8/DOPENP as the top lung-selective lipid nanoparticle (LNP) with superior pulmonary mRNA transfection. We elucidate that mononuclear phagocyte-guided cell-to-cell trafficking of bpLH15L2T8/DOPENP contributes to its high efficiency and selectivity of mRNA expression in lung tissue. p53 mRNA (mp53) delivered by bpLH15L2T8/DOPENP restores p53 function in p53-deficient pulmonary metastases and synergizes with immune checkpoint inhibitors to enhance antitumor immunity and inhibit lung metastasis of triple-negative breast cancer (TNBC). An all-trans retinoic acid (ATRA) prodrug-containing bpLNP is further developed for lung-specific codelivery of ATRA and mp53, which effectively suppresses lung metastasis of cancer stem cell-enriched TNBC.
Abstract from PubMed (PMID 42917407). This entry was added automatically by our daily literature monitor because it matches the topics we follow; read the full paper at the original source.
Related articles
Mathematical modeling in mRNA therapeutics: towards a pathway to individualized treatment protocols
Molecular pharmaceuticsCombined siRNA Targeting IκBα and Stat6 Promotes Macrophage Reprogramming toward Cancer Immunotherapy
The Journal of clinical investigationA single liver-sparing myotropic AAV ameliorates muscular dystrophy in humanized mice by base editing
Let's engineer the next delivery breakthrough together
We co-develop nanocarrier and biosensing programmes with pharma, biotech and academic groups — from target selection through scale-up.
